Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL)

2021 ◽  
pp. 1-4
Author(s):  
Francesco Malfona ◽  
Anna Maria Testi ◽  
Maria Luisa Moleti ◽  
Luigi Petrucci ◽  
Maurizio Martelli ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Salvage Treatment ◽  
Secondary Central Nervous System

Primary Central Nervous System Lymphoma Mimicking Longitudinally Extensive Transverse Myelitis

2020 ◽  
pp. 194187442096756
Author(s):  
Prashant Anegondi Natteru ◽  
Shashank Shekhar ◽  
Lakshmi Ramachandran Nair ◽  
Hartmut Uschmann
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Oligoclonal Bands ◽  
Relative Reduction ◽  
Thalamic Lesion ◽  
The Right

Primary central nervous system lymphoma (PCNSL) is an uncommon variant of extra-nodal non-Hodgkin’s lymphoma. Three regions can be involved in PCNSL: the brain, the spine, or the vitreus and retina. Spinal PCNSL is rare. It can mimic neoplasm, infection, and inflammation. Diagnostic confirmation is by tissue biopsy, and even then, tissue corroboration may be altered by an inflammatory overlay. We report a 59-year-old woman who we saw after she had 4 weeks of ascending tetraparesis plus bowel and bladder incontinence. Upon presentation, the patient was ventilator-dependent and locked-in. She reported normal sensation through eye-blinking. Magnetic resonance imaging (MRI) brain revealed signal intensity in the bilateral corona radiata and restricted diffusion in the right thalamus, whereas, MRI cervical, and thoracic spine showed T2 prolongation in the anterior medulla and upper cervical cord, with enhancement to C2-C3, and long segment hyperintensity from T1-T9 levels, respectively, suggestive of neuromyelitis optica spectrum disorder. Cerebrospinal fluid cytomorphology and flow cytometry were inconclusive for lymphoma/leukemia, but oligoclonal bands were present. Serum aquaporin-4 (AQP-4) antibodies were negative. MR spectroscopy demonstrated NAA reduction, mild lipid lactate peak, and relative reduction of choline on the side of the lesion, favoring demyelination. She received 5-days of intravenous methylprednisolone, followed by 7 sessions of plasma exchange without clinical improvement. Stereotactic biopsy of the right thalamic lesion revealed diffuse large B-cell lymphoma. PCNSL can mimic a demyelinating process early on, as steroid treatment could disrupt B-cell lymphoma cells, thus masking the correct diagnosis.

scholarly journals T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma

Rare Tumors ◽  
2015 ◽  
Vol 7 (4) ◽  
pp. 160-162 ◽  
Author(s):  
Pooja Advani ◽  
Jason Starr ◽  
Abhisek Swaika ◽  
Liuyan Jiang ◽  
Yushi Qiu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Primary Central Nervous System Lymphoma: Diffuse Large B-Cell Lymphoma

2019 ◽  
Vol 25 (4) ◽  
pp. 239-242
Author(s):  
Asuman Ali ◽  
Cemile Haki ◽  
Fatma Öz Atalay ◽  
Ramazan Yalçın
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Secondary Brain Lymphoma in a Case of Breast Diffused Large B-Cell Lymphoma: Case Report

2018 ◽  
Vol 5 (3) ◽  
pp. 113-114
Author(s):  
Hamed Javadian ◽  
Reza Jalili Khoshnood ◽  
Mohammad Reza Shahmohammadi ◽  
Seyed Amir Hassan Hosseini ◽  
Mohsen Keikhaee
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Risk Factor ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Brain Lymphoma ◽  
Large B Cell Lymphoma ◽  
Secondary Central Nervous System ◽  
Large B Cell

Secondary central nervous system lymphoma (SCNSL) is known as a rare disease. The risk factor of developing SCNSL is primary lymphoma type and site of involvement. We present a patient with an altered mental status known case of breast diffused large B-cell lymphoma (DLBCL) who underwent stereotactic biopsy because of a left periventricular mass lesion, which diagnosed as secondary brain lymphoma after pathologic typing. Because of limited data about the secondary central nervous system, lymphoma and it is a risk factor, we reported an aggressive breast DLBCL with brain involvement.

scholarly journals Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population

2019 ◽  
Author(s):  
Yuchen Wu ◽  
Yaming Wang ◽  
Xuefei Sun ◽  
Xueyan Bai ◽  
Jun Qian ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Dynamic Monitoring ◽  
Mri Features ◽  
Systemic Lymphoma ◽  
Secondary Central Nervous System ◽  
Aggressive B Cell Lymphoma

Abstract Background: Secondary central nervous system lymphoma (SCNSL) is defined as secondary central nervous system (CNS) involvement in patients with systemic lymphoma. It is considered a profoundly adverse complication with inferior clinical outcome. Parenchymal involvement in the CNS in aggressive B-cell lymphoma is not frequently seen and remains a diagnostic dilemma. Methods: In our study, we retrospectively analyzed the clinical and magnetic resonance imaging (MRI) features of 26 parenchymal SCNSL patients. In addition, we compared MRI features of SCNSL and primary CNS lymphoma (PCNSL) patients after 1:1 propensity score matching. Also we presented two SCNSL cases with atypical MRI appearance. Results: Among SCNSL patients, the median CNS relapse time was 3 months, and multiple lesions were found in 76.9% of the cases. In PCNSL, this percentage was 42.3% (p=0.011). None of the SCNSL patients and 23.1% of the PCNSL patients had solitary infratentorial lesions (p=0.003). Conclusions: The majority of parenchymal involvement occurred within the first year of systemic lymphoma, in which mostly cases presenting with multiple and supratentorial locations, unlike what was found in PCNSL. Moreover, nonenhancement MRI could not rule out the possibility of SCNSL, T2 Flair may provide more information, and dynamic monitoring on MRI could help in patient diagnosis.

scholarly journals Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement

2022 ◽  
Author(s):  
Serkan Akin ◽  
Chitra Hosing ◽  
Issa F. Khouri ◽  
Sairah Ahmed ◽  
Amin Alousi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Secondary Central Nervous System ◽  
Large B Cell

Secondary central nervous system large B-cell lymphoma (SCNSL) is rare with a generally poor prognosis. There is limited data about the role of autologous stem cell transplantation (ASCT) in these high-risk patients. We explored in this study treatment outcomes and prognostic factors for patients with SCNSL who underwent ASCT. We included all consecutive patients who underwent ASCT at our institution. Primary endpoints were progression free survival (PFS) and overall survival (OS). One-hundred two patients were identified. Median age at transplant was 56 (range, 21-71) years. With a median follow-up of 56 (range, 1-256) months, the median PFS and OS were 40 and 88 months, respectively. The 4-year PFS and OS were 48% and 57%, respectively. In univariate analysis, complete remission (CR) at transplant, prior lines of therapy (≤2), normal LDH, and parenchymal involvement were significantly associated with improved PFS. For OS, only CR at transplant and ≤2 prior lines of therapy were associated with improved survival. On multivariable analysis for PFS, CR at transplant (HR 0.278, 95% CI: 0.153-0.506; p=<0.0001) and ≤ 2 prior lines of therapy (HR 0.485, 95% CI: 0.274-0.859; p=0.0131) were significantly associated with superior PFS. Similarly, CR at transplant (HR 0.352, 95% CI: 0.186-0.663; p=0.0013) and ≤ 2 prior lines of therapy (HR 0.476, 95% CI: 0.257-0.882; p=0.0183) were associated with improved survival. In the largest single center study, our findings indicate that ASCT is associated with durable responses and prolonged survival in patients with SCNSL. Patients in CR at transplant and those received less than two lines of therapy have particularly excellent outcomes.

Sign in / Sign up

Export Citation Format

Share Document